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Introduction
Liquid mineral oil or light paraffin oil has been used as a placebo in clinical 
trials of icosapent ethyl including MARINE, ANCHOR, and REDUCE –IT. Mineral
oil was chosen as a suitable placebo to mimic the consistency, color, and 
odorless properties of icosapent ethyl capsules. Since the results of REDUCE-
IT, a few have raised questions regarding biological activity of mineral oil 
placebo due to small changes in some cardiac biomarkers including lipid 
levels and inflammatory markers in placebo arm patients, asking whether 
the mineral oil utilized in placebo capsules was physiologically inert or not.1 
Mineral oil has been utilized in humans as a laxative for decades (typically in 
doses of 15 – 45 grams/day), and the general safety has been inferred from 
clinical utilization. The ~2 grams twice per day of light liquid mineral oil 
taken by placebo group patients in clinical trials equates to less than a 
teaspoon per day.
EVAPORATE is an ongoing randomized, placebo-controlled trial that 
evaluates the effect of icosapent ethyl 4 grams daily in statin treated 
patients with elevated triglycerides on coronary plaque progression by 
coronary computed tomography angiography (coronary CTA) compared with 
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mineral oil placebo to provide important imaging-derived mechanistic 
information that can add insight to clinical outcomes from REDUCE-IT.2 
Coronary plaque volumes, including total plaque and total non-calcified 
plaque derived by coronary CTA, have been measured and are known to be 
associated with myocardial ischemia and adverse cardiac outcomes.3-5 In the 
present observational study, we sought to compare differences in 
progression of total plaque and total non-calcified plaque  volumes on 
coronary CTA in mineral oil placebo patients from EVAPORATE versus the 
non-mineral oil placebo arm from another randomized clinical trial, GARLIC 
5.6 We hypothesized that progression of total plaque and total non-calcified 
plaque volumes on coronary CTA is independent of consumption of mineral 
oil placebo capsules.
Methods
The study design and rationale for EVAPORATE and GARLIC5 have been 
published previously.2, 6 Eligible patients in EVAPORATE had known coronary 
atherosclerosis, elevated triglycerides (200–499 mg/dL), and low-density 
lipoprotein levels (LDL‐C) ≤115 mg/dL while on statins. In GARLIC5, to be 
eligible, participants had coronary artery calcium scores greater than 20 and 
known history of diabetes mellitus (DM).
We acquired coronary CTA scans for evaluation of coronary plaque volume at
baseline and at 12 months in GARLIC5 subjects and at baseline and at 9 
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months in EVAPORATE subjects. We performed quantitative plaque 
assessment using semi-automated plaque analysis software (QAngioCT 
Research Edition Version 2.0.5; Medis Medical Imaging Systems).7 
Pharmaceutical grade mineral oil placebo used in EVAPORATE consisted of a 
purified liquid mixture of straight chain saturated hydrocarbons that met the 
compendial requirements of the United States National Formulary (NF) for 
light mineral oil and of the European Pharmacopoeia (Ph. Eur.) for light liquid
paraffin oil.8, 9 The total daily dose of mineral oil placebo was four 1 g soft 
gelatin capsules, with two capsules taken twice daily with meals. The 
material does not contain any functional groups and is virtually free of all 
aromatic hydrocarbons and unsaturated hydrocarbons, making it chemically 
inert and allowing for minimal absorption. The composition of physiologically 
inert placebo powder (P-31) in GARLIC5 includes (per 100 mg) 
microcrystalline cellulose: 89.83 mg, hydroxypropyl cellulose:10.07 mg, and 
caramel 0.10 mg.
Analysis of covariance test was used to examine rates of progression 
between the groups. The final model was adjusted for baseline plaque, age, 
sex, diabetes status, baseline triglyceride levels, and statin use. Total plaque
and total non-calcified plaque volumes were log transformed to achieve a 
normal distribution. A P value of <0.05 was considered significant. SAS 
software (version 9.4) was used for analyses.
Results
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Mean (SD) age of participants (n=60) was 59 (9.9) years and 66% were 
male. A total of 28 participants from the GARLIC5 placebo arm and 32 
participants from the EVAPORATE placebo arm were analyzed. Participants 
had mean follow up of 10.8 months. Baseline characteristics of the cohorts 
are listed in Table 1. There were no significant differences in major clinical 
characteristics including age, body mass index (BMI), hypertension, levels of 
LDL, total cholesterol, hs-CRP, or use of medications, including aspirin and 
statins. Due to eligibility criteria of the trials, the GARLIC5 placebo cohort 
was more likely to have diabetes and take diabetes medications, while the 
EVAPORATE placebo cohort was more likely to have high triglycerides.
 
Mean levels of total plaque and total non-calcified plaque volumes were 
similar at baseline in both cohorts. Mean (SD) level of log total plaque 
volume at baseline was 4.85 (1.24) mm3 in the EVAPORATE and 5.49 (1.45) 
mm3 in the GARLIC5 placebo cohorts (p = 0.07). Mean (SD) level of log total 
non-calcified plaque volume at baseline was 4.5 (1.26) mm3 in the 
EVAPORATE and 5.25 mm3 (1.53) in the GARLIC5 placebo cohorts (p = 0.04). 
At follow up, mean (SD) level of log total plaque volume was 5.23 (1.17) mm3
in the EVAPORATE and 5.78 (1.18) mm3 in the GARLIC5 placebo cohorts (p = 
0.08). Mean (SD) level of log total non-calcified plaque volume was 5.01 
(1.14) mm3 in the EVAPORATE and 5.54 mm3 (1.21) in the GARLIC5 placebo 
cohorts (p = 0.09). In a univariate covariance of analysis test, when adjusted
for baseline plaque, there were no significant differences in progression of 
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log total plaque volume (β: 0.03± 0.13, p = 0.84) or log total non-calcified 
plaque volume (β: 0.01 ± 0.16, p = 0.94) between the placebo participants 
in EVAPORATE and GARLIC5. Adjusted multivariable analysis of covariance 
tests also did not show any significant differences in progression in log total 
plaque volume (β: 0.04± 0.13, p = 0.78) (Figure 1) or log total non-calcified 
plaque volume (β: 0.09 ± 0.17, p = 0.58) between the two groups.
Discussion
We report that there were no significant differences in progression of total 
plaque and total non-calcified plaque volume by coronary CTA in mineral oil 
placebo participants compared with non-mineral oil placebo participants 
drawn from two different randomized, placebo-controlled trials. We did not 
observe any significant relationship between mineral oil placebo 
consumption and progression of coronary plaque volumes by coronary CTA 
in our multivariable analysis. The EVAPORATE trial, to our knowledge, is the 
first randomized trial with mineral oil placebo to study effects on coronary 
plaque imaging by coronary CTA. Coronary plaque volumes are associated 
with the pathogenesis of coronary artery disease.
Our results are consistent with prior omega-3 fatty acid trials that suggest no
effect of mineral oil on surrogate markers of coronary artery disease, 
including triglycerides, LDL-C, fatty acids, and markers of inflammation in 
placebo arm participants.10, 11 Changes in levels of LDL-C and inflammatory 
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markers have been commonly observed in statin-stabilized patients in 
clinical trials.12 In a randomized trial of omega 3 ethyl ester vs control (no 
placebo) in participants with stable coronary artery disease, hsCRP levels 
were increased from baseline even in the control arm with no placebo.13 
These observations have been attributed to independent factors such as 
poor compliance with statins, time-dependent intra-individual variability of 
lipid/drug metabolism, and physiologic compensation to counteract statin-
induced decreases in lipids. Small changes in placebo group biomarker 
values in large clinical trials are also commonly observed due to the principle
of regression to the mean. A few have argued that mineral oil alters lipid 
levels by interfering with absorption of fat-soluble substances, including 
medications such as statins. In our analysis, there were no significant 
differences in use of antiplatelet or statins in the two groups analyzed, and 
our clear results on lack of differences in plaque progression between the 
two placebo groups demonstrates that there are no specific effects of low 
dose mineral oil on absorption of statins or other substances.
Our study has the following limitations. This is a post hoc analysis of 
observational data from two trials with differing inclusion criteria and thus 
subject to heterogeneity and residual confounding. The natural history of 
coronary atherosclerosis is known to differ between adults with and without 
diabetes, however, greater than 65% of EVAPORATE participants did have 
diabetes, and the presence of diabetes was accounted for in our 
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multivariable analysis.14 The sample size is small and given the post hoc 
design, the study was not powered to detect significant differences between 
the groups. The follow-up period of 10.8 months, although relatively short, is 
similar to some other trials evaluating progression of coronary 
atherosclerosis.2, 3
We conclude that progression of total plaque and total non-calcified plaque 
volumes on coronary CTA is not related to consumption of mineral oil in the 
quantities used in these placebo capsules.1, 2, 15 The results of REDUCE-IT and 
EVAPORATE, as well as several other trials using mineral oil placebo 
capsules, should not be affected by the choice of this placebo.
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